Finance

Lists
Q3 2026 earnings • released • EPS miss -32.54% • Revenue beat +0.99%
See results
RIGL:NASDAQ
Rigel Pharmaceuticals Inc
$39.65
-13.26%
(-6.06) 1D
$39.65
0.00% (0.00)
After hours
Closed: Nov 6, 4:00:00 PM GMT-5  ·   USD
All symbols
SymbolPriceChange% Change
Generating top insights for RIGL...
Open
$41.11
High
$41.67
Low
$37.60
Mkt. cap
740.66M
Avg. vol.
221.16K
Volume
759.19K
P/E ratio
2.47
52-wk high
$52.60
52-wk low
$24.95
EPS
$16.04
Beta
1.28
Shares outstanding
18.68M
No. of employees
173
Open
$41.11
High
$41.67
Low
$37.60
Mkt. cap
740.66M
Avg. vol.
221.16K
Volume
759.19K
P/E ratio
2.47
52-wk high
$52.60
52-wk low
$24.95
EPS
$16.04
Beta
1.28
Shares outstanding
18.68M
No. of employees
173
News stories
From web sources and news partners
About Rigel Pharmaceuticals Inc
CEO-
Employees173
Founded1996
HeadquartersSouth San Francisco, California, United States
SectorHealth Care
IndustryBiotechnology
Websiterigel.com
Analyst ratings
Based on 3 analysts giving stock ratings to RIGL in the past 3 months
Buy
Buy
1
Hold
2
Sell
0
12-month forecast
Based on 3 Wall Street analysts offering 12 month price targets for RIGL in the last 3 months.
Highest
Current $39.65
$85.00 (+114.38%)
Average
$60.33 (+52.16%)
Lowest
$47.00 (+18.54%)
Analyst
Recommendation
Action
Price target
Projected
Date
Kristen Kluska
Cantor Fitzgerald
Hold
Maintained
$47.00
+18.5%
11/05/2026
Joseph Pantginis
H.C. Wainwright
Buy
Reiterated
$85.00
+114.4%
11/04/2026
Allison Bratzel
Piper Sandler
Hold
Maintained
$49.00
+23.6%
10/21/2026
Yigal Nochomovitz
Citi
Buy
Maintained
$83.00
+109.3%
08/06/2026
Last report
Nov 5, 2026
Fiscal period
Q3 2026
$0.65 / $0.96
-32.54%miss
Revenue / Est. (USD)
80.89M / 80.10M
+0.99%beat
Fiscal Q3 2026 earnings call
Waiting for the earnings call
At a glance
Insights from the latest news and reports
Previous reportsAll values in USD
Loading Previous Earnings...
Revenue
Net income
All values in USD
Dec 2025
Mar 2026
Jun 2026
Sep 2026
Revenue
69.80M
58.82M
78.70M
80.89M
Cost of goods sold
16.64M
16.28M
22.49M
10.78M
Cost of revenue
16.64M
16.28M
22.49M
10.78M
Research and development expenses
-
-
-
18.27M
Total research and development expenses
-
-
-
-
Selling, general, and admin expenses
29.99M
30.65M
32.64M
34.73M
Operating expense
29.99M
30.65M
32.64M
53.00M
Total operating expenses
46.63M
46.93M
55.13M
63.78M
Operating income
23.17M
11.88M
23.58M
-
Other non operating income
-
-
-
-
EBT including unusual items
22.71M
11.66M
23.58M
17.41M
EBT excluding unusual items
22.71M
11.66M
23.58M
17.41M
Income tax expense
-245.35M
3.00M
6.30M
4.22M
Effective tax rate
-1,080.18%
25.76%
26.69%
24.26%
Other operating expenses
-
-
-
-
Net income
268.06M
8.65M
17.29M
-
Net profit margin
384.04%
14.71%
21.97%
16.30%
Earnings per share
1.12
0.44
0.88
0.65
Interest and investment income
1.24M
1.20M
789.00K
561.00K
Interest expense
-1.70M
-1.43M
-779.00K
-257.00K
Net interest expenses
-456.00K
-228.00K
10.00K
304.00K
Depreciation and amortization charges
-
-
-
-
EBITDA
23.77M
12.48M
24.42M
-
Gain or loss from assets sale
-
-
-
-
Insider transactions
Insider transactions data is drawn from third-party sources. Learn more
Insider
Position
Type
Date
Shares
Amount
Page 1
Upcoming events
AI content may include mistakes. Learn more
HelpSend feedbackPrivacyTermsDisclaimer
Google apps